Why the study?
Optimal therapeutic strategies for virus-induced systemic vasculitides require consideration of disease etiology and pathogenesis to improve patient outcomes.
Does the combination of antiviral treatments and plasma exchanges improve outcomes in patients with virus-induced systemic vasculitides?
Does the combination of antiviral treatments and plasma exchanges improve outcomes in patients with virus-induced systemic vasculitides?
The combination of antiviral therapy and plasma exchange is an effective, pathogenesis-adapted treatment strategy for certain virus-induced vasculitides like PAN and HIV-related vasculitis.
May support etiology-specific antiviral plus plasma exchange in virus vasculitides; leaves open confirmation by randomized trials.
The best therapeutic strategy in virus-induced vasculitides should take into account the etiology of the disease and be adapted to the pathogenesis. The combination of antiviral treatments and plasma exchanges has been proven effective in polyarteritis nodosa (PAN). In human immunodeficiency virus (HIV)-related vasculitis this strategy is also effective and does not jeopardize, like cytotoxic agents, the outcome of AIDS. In vasculitis related to HCV-associated cryoglobulinemia, plasma exchanges improve the outcome but the poor effectiveness of antiviral drugs is not able to favor, usually, a definite recovery of the patients and relapses are frequent.
No takes yet. Share an insight, caveat, or question.
Loı̈c Guillevin (2004) conducted a review in Virus-induced systemic vasculitides. Antiviral treatments and plasma exchanges was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: